MARKET

JAZZ

JAZZ

Jazz Phrmt
NASDAQ

Real-time Quotes | Nasdaq Last Sale

176.10
+1.51
+0.86%
After Hours: 176.10 0 0.00% 17:43 05/10 EDT
OPEN
177.09
PREV CLOSE
174.59
HIGH
177.99
LOW
173.43
VOLUME
759.79K
TURNOVER
--
52 WEEK HIGH
178.64
52 WEEK LOW
101.81
MARKET CAP
10.02B
P/E (TTM)
19.33
1D
5D
1M
3M
1Y
5Y
Asparaginase Market Expanding to Surpass USD 423.2 Mn by 2027
May 10, 2021 (Market Stats News via COMTEX) -- According to QY Research Medical, the global Asparaginase market size is projected to reach US$ 423.2 million...
Market Stats News · 13h ago
Bionical Emas launches Expanded Access Program for JZP458 - a recombinant Erwinia Asparaginase
, , /PRNewswire/ -- Bionical Emas, a global specialist Clinical Research Organization (CRO), has today announced the launch of a U.S. Expanded Access Program for Jazz Pharmaceuticals' investigational therapy JZP458 (asparaginase (recombinant)) for the tr...
PR Newswire - PRF · 14h ago
The Week In Cannabis: The New Tilray, Jazz-GW Pharma, Earnings, M&A, And More
This was an eventful week for the cannabis industry.
Benzinga · 3d ago
--UBS Adjusts Price Target on Jazz Pharmaceuticals to $236 From 228, Maintains Buy Rating
MT Newswires · 3d ago
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Inspire Medical Systems (INSP) and NeoGenomics (NEO)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ), Inspire Medical Systems (INSP)
SmarterAnalyst · 3d ago
Alprazolam Market Size 2021 Share, Growth By Top Company, Business Opportunity, Region, Application, Driver, Trends and Forecasts By 2023
The Express Wire · 3d ago
Myelodysplastic Syndrome (MDS) Treatment Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast - 2025
Japan, Japan, Thu, 06 May 2021 07:32:54 / Comserve Inc. / -- The report analyze market size, share, growth, trends, segmentation, top key players,...
Comserve · 4d ago
Jefferies Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
In a report released yesterday, David Steinberg from Jefferies maintained a Buy rating on Jazz Pharmaceuticals (JAZZ), with a price target of $214.00. The
SmarterAnalyst · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JAZZ. Analyze the recent business situations of Jazz Phrmt through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JAZZ stock price target is 204.35 with a high estimate of 236.00 and a low estimate of 176.00.
EPS
Institutional Holdings
Institutions: 750
Institutional Holdings: 61.24M
% Owned: 107.64%
Shares Outstanding: 56.90M
TypeInstitutionsShares
Increased
157
2.75M
New
93
846.56K
Decreased
196
4.84M
Sold Out
42
744.02K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.20%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Chief Executive Officer/Director
Bruce Cozadd
President/Chief Operating Officer
Daniel Swisher
Chief Financial Officer/Executive Vice President
Renee Gala
Executive Vice President/General Manager
Kimberly Sablich
Executive Vice President
Robert Iannone
Senior Vice President/General Counsel
Neena Patil
Senior Vice President
Finbar Larkin
Senior Vice President
Samantha Pearce
Chief Accounting Officer/Vice President
Patricia Carr
Director
Jennifer Cook
Director
Mark Smith
Independent Director
Paul Berns
Independent Director
Patrick Enright
Independent Director
Peter Gray
Independent Director
Heather McSharry
Independent Director
Heather Mcsharry
Independent Director
Seamus Mulligan
Independent Director
Kenneth O'Keefe
Independent Director
Anne O'Riordan
Independent Director
Norbert Riedel
Independent Director
Elmar Schnee
Independent Director
Catherine Sohn
Independent Director
Rick Winningham
No Data
  • All
  • Financials
  • Insiders
More
About JAZZ
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Webull offers kinds of Jazz Pharmaceuticals PLC stock information, including NASDAQ:JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.